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In 1995 the crude incidence of prostate cancer in France was
estimated to be 260–300 out of 100000 for men aged between 60
and 70 years and over 500 out of 100000 for men over 70 years of
age. The majority of men (73%) are diagnosed when they are over
70 years old. The standardised incidence increased from 51.8 to
87.1 between 1985 and 1995. It has been estimated that in 1995,
26474 new cases were diagnosed in France. The use of diagnostic
tests has contributed to an increase in the number of patients
detected with local or locoregional disease. The crude mortality
rate for prostate cancer in France was 32.8 out of 100000 in 1995,
and remains stable.
OBJECTIVES
The objectives of these recommendations are to define good
clinical practice guidelines for the diagnosis and treatment of
patients with nonmetastatic prostate cancer. The management of
patients with stage T4 cancer is not specifically covered in this
document, but some of the studies appraised also included patients
with this stage of cancer.
METHODS
The details of the methodology have been published previously
(Fervers et al, 2001). For this particular SOR, a multidisciplinary
group of experts was set up by the French National Federation of
Cancer Centres (FNCLCC) and the French Urology Association
(Association Franc¸aise d’Urologie: AFU) to appraise critically the
available evidence on the diagnosis and treatment of patients with
prostate cancer. Medline
s was searched from 1966 to 2000. This
bibliography was completed by the references of the members of
the working group, and a search for clinical practice guidelines
published on the Internet. The working group selected and
critically appraised pertinent references and then proposed the
‘Standards’, ‘Options’ and ‘Recommendations’ (SORs) for the
diagnosis and treatment of patients with nonmetastatic prostate
cancer, based on either the best available evidence or expert
agreement.
‘Standards’ identify clinical situations for which there exist
strong indications or contra-indications for a particular
intervention and ‘Options’ identify situations for which there are
several alternatives, none of which have shown clear superiority
over the others (Table 1). In any SOR, there can be several
‘Options’ for a given clinical situation. ‘Recommendations’ enable
the ‘Options’ to be weighted according to the available evidence.
Several interventions can be recommended for the same clinical
situation, so that clinicians can make a choice according to
specific clinical parameters, for example, local circumstances,
skills, equipment, resources and patient preferences. Adapting
the SORs to a local situation is possible if the reason for the choice
is sufficiently transparent and this is crucial for successful
implementation. Inclusion of patients in clinical trials is an
appropriate form of patient management in oncology and
is recommended frequently within the SORs, particularly
in situations where evidence is too weak to support an
intervention.
The type of evidence underlying any ‘Standard’, ‘Option’o r
‘Recommendation’ is indicated using a classification developed by
the FNCLCC based on previously published models. The level of
evidence depends not only on the type and quality of the studies
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When no clear scientific evidence exists, judgement is made
according to the professional experience and consensus of the
expert group (‘expert agreement’).
The document containing the Standards, Options and Recom-
mendations was then reviewed by a group of independent experts
(see Appendix) and after taking into consideration their com-
ments, the guidelines were validated by the working group.
This is a translation of the summarised version based on the full
text (in French) which has been published as a monograph (Villers
et al, 2002) and which is also available on the FNCLCC web site
(http://www.fnclcc.fr). These clinical practice guidelines will be
updated when new evidence becomes available or if there is a new
consensus among the experts.
RISK FACTORS
Family history (inherited or familial forms) and ethnogeographical
origins (particularly African) enable high-risk groups to be defined
as a priority for targeted screening (annual digital rectal
examination and serum PSA determination in men over 40 years
old).
CLASSIFICATION OF PROSTATE ADENOCARCINOMA
The 1997 TNM classification, modified by the criteria of the
American Joint Cancer Committee for stage T1a and T1b cancers,
should be used (standard). A cancer should be classed as stage T1a
when it accounts for at least 5% of the resected tissue (by
transurethral or simple prostatectomy) with a Gleason score under
7 (i.e. no grade 4 or 5 disease) (standard).
Prior to surgery, patients should be stratified by their initial PSA
concentration, the ratio of number of positive biopsies to the total
number of biopsies and the percentage of grade 4/5 disease, in
order to evaluate the response to treatment (option). Histo-
pathological findings from the radical prostatectomy specimen
should be documented (option), as they are independently
correlated with prognosis (i.e. the risk of PSA recurrence after 5
years). The three relevant criteria are the total tumour volume, the
extent of any poorly differentiated tumour (Gleason grades 4 and
5) and tumour localisation outside or within the transition zone
(option).
PATHOLOGY
Histological diagnosis on biopsy specimens
The diagnosis of prostatic adenocarcinoma is generally made using
routine haematoxylin and eosin staining and is based on structural
and cytological findings (standard). If an isolated area of high-
grade prostatic intraepithelial neoplasia (PIN) or atypical or
borderline lesions are detected, serial sections of all resected tissue
should be made to locate any foci of microscopic carcinoma
(standard). Anti-PSA and anti-PAP antibodies can be used to
detect metastatic sites in those patients with poorly differentiated
tumours of uncertain prostatic or urethral origin (standard).
Immunohistochemistry with anti-cytokeratin 903 antibodies is a
complementary diagnostic tool. The results should be interpreted
in conjunction with the histological findings obtained using
standard techniques (option).
Gleason score
The Gleason grading system is the standard staging system and the
following rules should be applied:
 the Gleason grade(s) apply(ies) to the dominant growth patterns;
 the Gleason score corresponds to the sum of the two dominant
grades; when three grades are present, the highest grade and the
dominant grade should be used;
 the modified Gleason score should indicate the proportion of
grade 4 and 5 disease present (option).
Tumour grade should not be assessed in those patients who have
been treated with radiotherapy or hormonal therapy. The use of
the modified Gleason score, that is, proportion of grade 4 and 5
disease, is recommended.
Histological types and histoprognostic factors
The majority of malignant prostatic tumours are adenocarcinomas
originating from the glands in the peripheral and transition zones.
The histoprognostic factors that should be determined are:
histological type; the modified Gleason score and the Gleason
score; the pathological classification (TNM 97); extraprostatic
extension; invasion of the seminal vesicles; the status of the
margins and the nodal status (standards). Two other factors can be
taken into consideration: perineural invasion and tumour volume
(options).
Pathology report
Prostatic biopsies The pathology report for prostate biopsies
should specify: the length of the biopsy core in millimetres; its
quality (mentioning any breaks); the length of tumour involvement
in millimetres or as a percentage of the biopsy length; the Gleason
score and the presence of any capsular, pericapsular or extrapro-
static extension (standard). Only high-grade PIN lesions should be
noted. If these are isolated, all biopsy tissue should be examined
for the presence of infiltrating microfoci.
The report can contain a diagrammatic representation (or table)
of the results and the modified Gleason score (proportion of grades
Table 1 Definition of ‘Standards, Options and Recommendations’
Standards Procedures or treatments that are considered to be
of benefit, inappropriate or harmful by unanimous decision
based on the best available evidence
Options Procedures or treatments that are considered to be
of benefit, inappropriate or harmful by a majority, based on
the best available evidence
Recommendations Additional information to enable the available options
to be ranked using explicit criteria (e.g., survival toxicity)
with an indication of the level of evidence
Table 2 Definition of level of evidence
Level A
There exists a high-standard meta-analysis or several high-standard randomised
clinical trials that give consistent results
Level B
There exist good quality evidence from randomised trials (BI) or prospective or
retrospective studies (B2). The results are consistent when considered together
Level C
The methodology of the available studies is weak or their results are not consistent
when considered together
Level D
Either the scientific data do not exist or there is only a series of cases
Expert agreement
The data do not exist for the method concerned, but the experts are unanimous
in their judgement
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of affected areas should be summarised in an agreed format.
In the absence of any definite malignant change, dystrophic
lesions described in the report should not be mentioned in the
conclusion, unless there is extensive destruction due to prostatitis
(recommendation).
Transurethral resection specimens All the resected cores, up to
eight blocks, should be included (standard). When there are large
amounts of tissue, an extra block should be included for each 5g of
resected tissue (standard). In certain situations, depending on the
clinical context (e.g., a young patient or an elevated PSA
concentration), it may be necessary to analyse all resected tissues
immediately. There is no consensus as to the number of
histological blocks that should be made from tissue from a simple
suprapubic prostatectomy. A minimum of one block for every 5g
of tissue should be fixed, depending on the macroscopic
appearance of the tissue (recommendation).
The report should specify: the histological type of the cancer; the
percentage of Gleason grades 4 or 5 and the Gleason score; the
proportion of involved cores as a percentage of the total number of
cores; and any extraprostatic extension (standard). The report
should include (option): presence of perineural invasion; vascular
invasion; PIN foci; post-therapeutic changes; atypical adenoma-
tous hyperplasia and benign hypertrophy.
Radical prostatectomy specimen The prostate should be exam-
ined using the Stanford serial section technique. The report should
specify: histological type; Gleason score; pathological stage
(pTNM, 1997); presence of extraprostatic and seminal vesicle
invasion and the status of margins (standard). The report can
include: the proportion of grades 4 and 5 (modified Gleason
score); tumour volume (estimated in terms of the volume of the
gland); tumour localisation (peripheral or transitional zone –
benign hypertrophy); any associated lesions; perineural invasion;
microvascular invasion and post-therapeutic changes (option).
The inclusion of all prostatic sections guarantees the best
assessment of the excision margins (recommendation).
Pelvic lymphadenectomy specimen A frozen section can be
examined prior to the definitive histopathological evaluation
(option). The latter, performed following fixation, should include
all nodes removed. They should be sectioned at several levels to
increase the likelihood of detecting any micrometastases (stan-
dard).
METHODS OF DETECTION (FIGURES 1 AND 2)
Rectal examination
Any anomaly detected during digital rectal examination suggestive
of prostate cancer in the absence of infection should be
investigated further with a transrectal ultrasound-guided biopsy
even if the PSA concentration is normal (standard).
PSA determination
Total serum PSA determination (upper limit of the reference
range: 4mgl
1) remains the reference test for screening and the
primary indication for biopsy (standard). The value of free PSA
determination in cancer screening remains to be determined.
There is no consensus as to how often PSA concentrations should
be determined. Repeated PSA determinations should be performed
by the same laboratory using the same technique (standard). A
lower upper limit of the reference range for total serum PSA
concentration (between 2 and 4mgl
1) can be used in men under
65 years old or those at risk (option). The adjustment of the upper
limits of the reference range for PSA concentration, using age and
prostatic volume (PSA density), has not been validated against the
decision to perform biopsies (recommendation).
Imaging
There is no indication for imaging in the primary diagnostic work-
up (standard). Magnetic resonance imagery (MRI) and colour
Doppler ultrasound are under evaluation for the detection of
cancer following a negative result from initial biopsies (recom-
mendation).
Figure 1 Tumour stage according to method of detection.
Figure 2 Diagnostic investigation for patients with abnormal serum PSA
concentration (T1c) and/or suspicious digital rectal examination or imaging
studies (T2, T3,).
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A diagnosis of prostate cancer is made following the histopatho-
logical examination of prostatic biopsy samples (standard).
Transurethral resection is not recommended as a first-line biopsy
if prostate cancer is suspected (standard). In potentially curative
situations, at least six systematic transrectal ultrasound-guided
biopsies, sampling particularly the posterior zone, should be taken.
The aim and the practical aspects of this investigation should be
explained to the patient (standard). Rectal preparation by enema
and prophylactic antibiotics effective against Gram negative
bacteria should be performed to prevent infectious complications
(standard).
The biopsies can be performed either in a day-hospital or
outpatient setting, usually with local anaesthesia only (option). In a
minority of patients, locoregional or general anaesthesia may be
necessary. Additional biopsies may be performed on any zones
found to be abnormal on clinical or ultrasound examination
(option). When curative treatment is not planned, fewer biopsies
can be performed (option). A more extensive procedure with 10
biopsies can be undertaken if the first series of biopsies gives
negative results. The patient should be informed about the risks of
this investigation. They must have the contact details of the
emergency department they should contact, if any complications
should occur.
Indications and strategies for further biopsies after the diagnosis of
PIN or suspicious lesions (Figure 2) Only high-grade PINs should
be noted on the histopathological report of the biopsy (standard,
level of evidence: B2). The diagnosis of a high-grade PIN
should not lead to a treatment plan (standard, expert agreement).
A further series of biopsies should be performed within 3
months in situations where PIN or suspicious lesions have been
diagnosed (standard, expert agreement). When curative treatment
is not planned (life expectancy of less than 10 years, patient’s
choice, etc.), further biopsies are not recommended (recommen-
dation).
Further prostate biopsies after initial negative biopsy
(Figure 2) When curative treatment is not planned, an additional
work-up is not indicated (standard). When curative treatment is
planned there are two possible options: (1) no further biopsy; (2)
wait for 3 months and then re-evaluate with serum PSA
determination and ultrasound-guided biopsy. Depending on the
degree of suspicion, the additional work-up for re-evaluation can
include: PSA velocity and the percentage of free PSA; a further
series of biopsies including the transition zone (the number of
biopsies can be increased by including laterally directed biopsies
in the peripheral zone) or a transurethral resection (option). If the
test result is suspicious (PSA concentration, digital rectal
examination), a second series of biopsies is recommended
(recommendation).
Management of patients following a diagnosis of stage T1a or T1b
cancer (Figure 3) There are two therapeutic options possible for
patients with a life expectancy of more than 10 years: primary
curative treatment or evaluation of the remaining prostate to
confirm the presence of residual tumour. The remaining prostate
should be biopsied if the postoperative digital rectal examination is
abnormal, and/or the 3-month postoperative PSA concentration is
higher than 4mgl
1 or has been reduced by less than 50%. If the
results of the biopsies of the remaining prostate are negative,
clinical surveillance and determination of serum PSA concentra-
tions should be performed every 6 months (option). If the biopsies
of the remaining prostate are positive, curative treatment should
be undertaken. Curative treatment is not recommended for
patients with a life expectancy of less than 10 years (recommenda-
tion, expert agreement).
STAGING (FIGURE 4)
Staging by clinical examination and imaging
Digital rectal examination and a transrectal ultrasound should be
performed prior to, and used as a guide for, biopsies of the
periprostatic tissue and seminal vesicles (standard). A renal
ultrasound and CT scan should be performed for patients with
stage T3 cancer (standard). Pelvic or endorectal coil MRI can be
performed if radical prostatectomy or radiotherapy is indicated, if
extraprostatic extension is suspected and if the results could
modify the treatment plan (option).
Evaluation of periprostatic metastatic spread
Periprostatic metastatic spread can be evaluated by biopsy of the
seminal vesicles or the periprostatic tissue (option). These biopsies
should be taken at the same time as the first series of prostatic
biopsies if the results of the digital rectal examination, imaging or
the PSA concentration are suggestive of periprostatic involvement
(recommendation). Biopsies of the seminal vesicles should be
taken, as a second-line investigation, if the results of the biopsies
of the bases of the two prostatic lobes are positive (recommenda-
tion).
Imaging for node involvement
Abdominal and pelvic CT scan should be performed in patients
with: T2a stage disease or higher, a PSA concentration greater than
15mgl
1 and a Gleason score of at least 7 (standard). MRI for the
same indications is optional.
Lymphadenectomy for staging
Lymphadenectomy should be limited to the ilio-obturator regions
(standard) and should be performed in those patients undergoing
Figure 3 Management of patients with stage T1a and T1b tumours.
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perform a lymphadenectomy at the same time as radical
prostatectomy if the patient has good prognostic factors: that is,
stage T1 tumour; a Gleason score of under 6 and a pretherapeutic
PSA concentration of less than 10mgl
1 (option). An isolated
lymphadenectomy should not be undertaken prior to radio-
therapy. It can be performed if the risk of node invasion is high
(option).
Assessment of bone metastases by bone scan
Irrespective of the planned treatment, a bone scan is indicated
during the initial work-up in the presence of one of the following:
bone pain; a locally advanced prostatic lesion (at least T3Nx or T1-
4N1-3 or higher); the presence of Gleason grade 4 or 5 and a PSA
concentration of at least 10mgl
1 (standard). The interpretation of
the bone scan should be made in light of the patient’s PSA
concentration and clinical history (recommendation). In situations
other than those defined in this standard, the decision to
undertake a bone scan is left to the discretion of the physician,
with the knowledge that the average risk of bone metastases in this
situation in Europe is 3.3% (option, expert agreement). Additional
studies are needed to assess the prevalence of bone metastases in
situations other than those defined in the standard (recommenda-
tion).
FACTORS TO CONSIDER WHEN MAKING A
TREATMENT PLAN (FIGURES 5–7)
Criteria for assessing response to curative treatment
Screening using PSA concentration can detect stage T1c disease
and enables the detection of prostate cancer 4–5 years earlier than
the stage T2 tumours reported in early series. The median actuarial
delay between the appearance of metastases and death is 5 years.
Specific follow-up for a minimum of 15 years is necessary to
evaluate the efficacy of treatment of localised prostate cancer
(standard). A 10-year metastasis-free survival is an acceptable
criteria for evaluating treatment response for localised prostate
cancer (standard). The criterion for complete remission after
radical prostatectomy is an undetectable PSA concentration (under
0.1mgl
1) for at least 7 years after radical prostatectomy
(standard). The criteria for complete remission after external-
beam radiotherapy or brachytherapy have not yet been defined
(standard). The criterion for progression after radical prostatect-
omy, external-beam radiotherapy or brachytherapy is an increase
in PSA concentration measured on three successive occasions at
monthly intervals (standard). The median delay between an
increased PSA concentration and the appearance of metastases is
8 years (standard).
Prognostic factors related to the prostate tumour
Clinical tumour stage, Gleason score and the pretreatment PSA
concentration are prognostic factors for locoregional metastatic
spread and therefore, for treatment response (standard). Other
prognostic factors that can be used are: the Gleason grades present;
the number of affected biopsies; the extent of the tumour tissue in
the core biopsy and perineural invasion (option). Partin tables can
be used, before treatment, to evaluate the risk of extraprostatic
metastatic spread and pelvic node invasion (option).
Patient-related prognostic factors
Curative treatment should be offered to men with localised
prostate cancer if their life expectancy is at least 10 years. Life
Figure 4 Staging for a histologically proven invasive cancer.
Figure 5 Therapeutic management of patients with stage T1 or T2
tumours.
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population and the presence or absence of comorbidities likely to
have an impact on mortality.
TREATMENT: WATCH AND WAIT POLICY (FIGURE 8)
For patients with stage T1c or T2 prostate cancer with a life
expectancy of less than 10 years, a watch and wait policy can be
considered (option, level of evidence: C). In patients with a life
expectancy of less than 10 years, a watch and wait policy is even more
appropriate for lower stage disease and grade (recommendation).
TREATMENT: RADICAL PROSTATECTOMY
Prostatectomy is an effective treatment for stage T1a, T1b, T1c or
T2 prostate cancer (standard, level of evidence: B2). Prostatectomy
can be considered for stage T3 and pN1 cancers (option).
Prostatectomy should be undertaken in stage T3 and pN1 cancers
only in the setting of a randomised clinical trial assessing the
efficacy of prostatectomy alone or in combination with other
treatment (radiotherapy or hormone therapy) (recommendation).
Radical prostatectomy is not recommended for stage pN1 high-
grade tumours (Gleason score 47) (recommendation).
TREATMENT: EXTERNAL-BEAM RADIOTHERAPY
External-beam radiotherapy alone is an effective treatment for
stage T1, T2 or T3, N0, M0 prostate cancer (standard, level of
evidence: B2). The minimum recommended dose is 70Gy,
irrespective of the prognostic factors present (recommendation,
level of evidence: B2). Patients should be included in randomised
clinical trials assessing dose escalation.
Quality control for external-beam radiotherapy
Dosimetry, with CT planning, is recommended for defining the
target tumour volume (recommendation, level of evidence: B2).
Figure 6 Therapeutic management of patients with stage T3 tumours.
Figure 7 Therapeutic management of patients with stage N1 tumour
(imaging studies).
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Two types of external-beam radiotherapies are possible: conformal
or conventional (option, level of evidence: C). Conformal radio-
therapy reduces late toxicity compared with conventional radio-
therapy and should be used when giving high doses
(recommendation, level of evidence: C). Factors reported to affect
the risk of complications following external-beam radiotherapy are
transurethral prostatic resections prior to radiotherapy and the
dose of external-beam radiotherapy used.
Dose escalation
Patients with a good prognosis (T1–T2a, PSAo10mgl
1 and
Gleason score between 2 and 6) have not been shown to benefit
from dose escalation above 70–74Gy. Patients with an inter-
mediate prognosis receiving radiotherapy alone seem to benefit
most from a dose escalation above 74Gy.
TREATMENT: BRACHYTHERAPY
Retropubic brachytherapy for prostate cancer should no longer be
used (standard, level of evidence: C).
Brachytherapy with temporary implants
Technical data The isotope that should be used for brachyther-
apy is Iridium
192 (standard). Two types of brachytherapy can be
used: low-dose rate or high-dose rate (option).
Indications Dosimetric planning should be used. The combina-
tion of brachytherapy with temporary implants and external-beam
radiotherapy is a therapeutic option for locally advanced prostatic
cancer (option, level of evidence: D). Brachytherapy with
temporary implants should not be used for stage T1 or T2a
tumours outside the setting of a randomised clinical trial
(recommendation).
Brachytherapy with permanent implants
Technical data Dosimetric planning should be used either prior
to implantation or during the procedure (standard). The
recommendation from Task Group 43 (TG-43) is that brachyther-
apy dosimetric parameters should be used for calculating the dose
(standard, expert agreement). Postimplantation dosimetry should
be performed 4 weeks and 2–3 weeks after the implantation for
iodine 125 and palladium 103, respectively (standard). The patient
should be given information about radio-protective measures for
children and pregnant women, the need to use condoms and to
filter all urine and the need to inform physicians in the event of a
pelvic intervention (standard, expert agreement). Training in
brachytherapy techniques is essential and should be evaluated
(standard, level of evidence: B2).
It is not known whether freehand implantation or US/CT-guided
template systems give better results (option, level of evidence: D).
Similarly, there is no evidence that iodine 125 should be used in
preference to palladium 103 (option, level of evidence: C).
Transrectal ultrasound data should be used for predictive
dosimetry and implantation (recommendation, expert agreement).
The modified peripheral implantation technique is recommended
to minimise the risk of urethral overdose (more than 200% of the
prescribed dose) (recommendation, expert agreement). The
minimum peripheral doses recommended are 144Gy for iodine
125 in monotherapy and 100–110Gy in combination with
radiotherapy (40–50Gy) and 115 and 80–90Gy for palladium
103 (recommendation, expert agreement). The report should
specify: the volume implanted; the number of seeds implanted;
the number of needles used; the total activity and the prescribed
dose. Dosimetry should be performed following implantation
using CT scanning, with the calculation of dose-volume histograms
(DVHs). The recommended delay for postimplantation dosimetry
is 4 weeks for iodine 125 (and 2–3 weeks for palladium 103). The
data to be reported are:
 D100, D90 and D80: isodose covering 100 (minimal peripheral
dose), 90 and 80%, respectively, of the prostatic volume. A
good-quality implant will have at least a D90 of the dose
prescribed;
 V200, V150, V100, V90 and V80: the percentage of the prostatic
volume receiving 200, 150, 100, 90 and 80%, respectively, of the
dose prescribed;
 the total volume of the prostate obtained for the postimplanta-
tion dosimetry;
 the delay between the brachytherapy and the postimplantation
dosimetry;
 the doses received by the ureter and the anterior wall of the
rectum.
Indications Prostatic brachytherapy alone using permanent
implants is potentially curative in patients with the following
characteristics: clinical stage T1 or T2a disease (TNM 1992), a
Gleason score of 6 or lower and a PSA concentration of less than
10mgl
1 (option). Continued evaluation of this treatment is
recommended (morbidity, tumour control) in the setting of a
randomised clinical trial (recommendation).
Brachytherapy toxicity Brachytherapy is contraindicated in
patients who have undergone a previous large transurethral
resection (standard) and in patients with a previous limited
transurethral resection (recommendation). A prostatic volume of
more than 50–60cm
3 and/or the presence of hypertrophy in the
median lobe are relative contra-indications for brachytherapy
(recommendations). The modified peripheral implantation tech-
nique is recommended.
The use of questionnaires to evaluate urinary function prior to
implantation is recommended (level of evidence: C). The length of
ureter receiving more than 200% of the prescribed dose should be
Figure 8 Watch and wait policy.
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120% of the prescribed dose should be limited to 10 and 5mm,
respectively (expert agreement).
Prostatic biopsy to measure treatment response to
brachytherapy
Biopsies should not be performed until 18–24 months after
brachytherapy (recommendation).
TREATMENT: HORMONAL THERAPY ALONE
Hormone therapy alone for stage T1, T2, Nx or M0 cancer is not
indicated in the absence of progressive disease (standard).
Hormone therapy, either alone or in combination, can be
considered in patients with nonmetastatic disease if curative
treatment is not planned (option). This treatment modality is
under evaluation.
TREATMENT: CHEMOTHERAPY
The use of chemotherapy in nonmetastatic prostate cancer is not
recommended (option).
COMBINED TREATMENTS
Brachytherapy and hormonal therapy
The combination of brachytherapy and hormonal therapy may be
beneficial, compared with brachytherapy alone, in patients with an
intermediate prognosis (Gleason score of more than 7 and/or PSA
concentration higher than 10mgl
1) (option, level of evidence: C).
Combined brachytherapy and hormonal therapy should only be
proposed in the setting of a randomised clinical trial (recommen-
dation).
Brachytherapy and external-beam radiotherapy
The combination of external-beam radiotherapy and brachyther-
apy with permanent implantation can be considered in patients
with an intermediate prognosis (option). The benefits of this
combination should be evaluated against external-beam radio-
therapy alone, or in combination with hormonal therapy in the
setting of a randomised clinical trial (recommendation).
Brachytherapy, external-beam radiotherapy and hormonal
therapy
The combination of brachytherapy, external-beam radiotherapy
and hormonal therapy for patients with a poor prognosis should
only be considered in the setting of a randomised clinical trial
(recommendation).
Neoadjuvant hormonal therapy before prostatectomy
There is no benefit from neoadjuvant hormonal therapy for local
stage cancers (T1–T2) (standard, level of evidence: B1). Neoadju-
vant hormonal therapy before radical prostatectomy is not
indicated (option). Neoadjuvant hormonal therapy should not be
considered for stage T3 cancers, outside the setting of a
randomised clinical trial (recommendation, level of evidence: B1).
Prostatectomy and adjuvant hormonal therapy
Adjuvant hormonal therapy can be prescribed after radical
prostatectomy for patients with node involvement (option, level of
evidence: C). Patients with stage pT3 cancer and positive margins
should be included in randomised clinical trials to determine the
efficacy of adjuvant hormonal therapy (recommendation).
Prostatectomy and adjuvant radiotherapy
In patients with node involvement (pN1), adjuvant radiotherapy
after radical prostatectomy has not been shown to improve
outcome (option, expert agreement). Adjuvant radiotherapy may
be considered in patients with widespread stage pT3a cancer, or
with stage pT4 disease without node or seminal vesicle invasion or
with positive surgical margins, particularly if the postoperative
PSA concentration cannot be determined (option, level of
evidence: C). One potential advantage of adjuvant radiotherapy
is that the dose is lower than that used when treatment is deferred
until a rise in PSA is detected. Patients should be included in
randomised clinical trials to determine the efficacy of adjuvant
radiotherapy.
Hormonal therapy and radiotherapy
The combination of radiotherapy and long-term hormone therapy
can be considered in patients with locally advanced prostatic
cancer, stages T2b, T3, and/or Gleason score of at least 8 (option).
Short-term hormone therapy can be prescribed for patients with a
good prognosis (option). Since the optimal combination of
hormone and radiotherapy has not been established, combination
treatment should be used only in the setting of a randomised
clinical trial (recommendation).
Treatments under evaluation
Neutron therapy and transrectal treatment with targeted high-
intensity ultrasound are under evaluation. The efficacy of these
treatments should be assessed against the newest radiotherapy
techniques (recommendation).
POST-TREATMENT FOLLOW-UP (FIGURE 9
Follow-up after prostatectomy
Total serum PSA should be measured between 1 and 3 months
after radical prostatectomy (standard). Total serum PSA levels
should be measured every 3 months during the first year (or less
frequently if the concentration is below the limit of detection) and
every 6 months for the following 7 years if the concentration is
below the limit of detection (standard, level of evidence: B2).
Digital rectal examination is optional in patients with a total serum
PSA level below the limit of detection (option, expert agreement).
Follow-up after radiotherapy
After radiotherapy, follow-up should include PSA determination
and digital rectal examination for an indefinite period (standard,
expert agreement). PSA determination and digital rectal examina-
tion should be undertaken every 6 months (recommendation,
Figure 9 Post-treatment follow-up.
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serum PSA concentration is low (recommendation).
ACKNOWLEDGEMENTS
We thank the French Regional Comprehensive Cancer Centres, the
French Employment and Solidarity Ministry, the French associa-
tion: ‘Ligue Nationale Contre le Cancer’ and the French Hospital
Federation for their financial support. The SOR guidelines are a
collective production, created by the French National Federation of
Comprehensive Cancer Centres (Federation Nationale des Centres
de Lutte Contre le Cancer – FNCLCC), and they are protected by
intellectual property law. The FNCLCC holds the copyright for
these guidelines, and holds all the rights over copying, publication,
translation and dissemination.
REFERENCES
Fervers B, Hardy J, Blanc-Vincent MP, Theobald S, Bataillard A, Farsi F,
Gory G, Debuiche S, Guillo S, Renaud-Salis JL, Pinkerton R, Bey P, Philip
T (2001) SOR: project methodology. Br J Cancer 84 (Suppl 2), 8–16
Villers A, Pommier P, Bataillard A, Fervers B, Bachaud JM, Berger N,
Bertrand AF, Bouvier R, Brune D, Daver A, Fontaine E, Haillot O,
Lagrange JL, Molinie ´ V, Muratet JP, Pabot du Chatelard P, Peneau M,
Prapotnitch D, Ravery V, Richaud P, Rossi D, Soulie ´ M (2002) Fe ´de ´ration
Nationale des Centres de Lutte Centre le Cancer. (ed) Cancer de la
prostate non metastatique (Non M, Vol. 14. Paris: John Libbey
EUROTEXT; Standards Options & Recommendations
Appendix
Reviewers
A Alberti-Mourret (Centre Hospitalier, Belfort), P Arveux (Ho ˆpital
Saint-Jacques, Besanc¸on), M Assicot (Institut Gustave Roussy,
Villejuif), JC Baron (Clinique Saint-Gre ´goire, Tours), V Beckendorf
(Centre Alexis Vautrin, Vandoeuvre-le `s-Nancy), Ph Beuzeboc
(Institut Curie, Paris), P Bey (Centre Alexis Vautrin, Van-
doeuvre-le `s-Nancy), L Boccon-Gibod (CHU Ho ˆpital Bichat-Claude
Bernard, Paris), A Boneu (Institut Claudius Re ´gaud, Toulouse),
JL Bonnal (Ho ˆpital Victor Provo, Roubaix), B Bouabana
(Vizille), M Bouc (Nantes), C Carpuat (Bagne `res-de-Bigorre), M
Caudry (Ho ˆpital Saint Andre `, Bordeaux), L Chauveinc (Institut
Curie, Paris), B Chauvet (Clinique Sainte Catherine, Avignon), F
Cornud (avenue Robert Schuman, Paris), JM Cosset (Institut
Curie, Paris), A Couanon (Saint-Cloud), C Coulange (CHU Ho ˆpital
Salvator, Marseille), B Cuzin (Lyon), JL Davin (Clinique
Rho ˆne-Durance, Avignon), C Dejax (Centre Jean Perrin,
Clermont-Ferrand), A Delage (Saint-Michel), G de Pinieux
(Groupe hospitalier Cochin, Paris), G Ph Desbonnets (Fleurbaix),
JF Douard (Clinique Saint-Dominique, Flers), JB Dubois
(Centre Val d’Aurelle, Montpellier), B Dubray (Centre Henri
Becquerel, Rouen), I Durand-Zaleski (Ho ˆpital Henri Mondor,
Cre ´teil), G Escourrou (CHU Rangueil, Toulouse), R Fourcade (CH
d’Auxerre, Auxerre), Y Fulla (Ho ˆpital Cochin, Paris), JP Ge ´rard
(Centre Hospitalier Lyon-Sud, Pierre-Be ´nite), F Giammarile
(Centre Le ´on Be ´rard, Lyon), Ph Gomez (Rouen), R Gonthier
(CHU Ho ˆpital de la Charite ´, Saint-Etienne), J Goussard (Centre
Franc¸ois Baclesse, Caen), F Guerber (SCM B 12, Grenoble),
B Guilloneau (Institut Mutualiste Monsouris, Paris), L Guy
(Ho ˆpital Gabriel Montpied, Clermont-Ferrand), P Hardouin
(Institut Calot, Berck), O He ´le ´non (Ho ˆpital Necker, Paris),
A Houlgatte (HIA du Val de Gra ˆce, Paris), F Iborra (Montpellier),
J Irani (CHU La Mile ´trie, Poitiers), G Kouri (boulevard de Ve ´sone,
Pe ´rigueux), J Lambert (Saint-Avold), E Lartigau (Centre Oscar
Lambret, Lille), S Legrain (Ho ˆpital Bichat, Paris), L Lemaı ˆtre
(CHRU Ho ˆpital Huriez, Lille), D Le ´onard (Boulogne-sur-Mer), E
Leprise-Fleury (Centre Euge `ne Marquis, Rennes), A Lesourd (IMM
Choisy, Paris), JP Maire (Ho ˆpital Saint Andre ´, Bordeaux), C
Mazerolle (CHU Purpan, Toulouse), JJ Mazeron (CHU la
Salpe ´trie `re, Paris), JF Minne (Clinique radiologique des Dentel-
lie `res, Valenciennes), B Minsky-Kravetz (Luce), JL Moreau
(Nancy), N Mottet-Auselo (CHU G Doumergue, Nı ˆmes), TD
Nguyen (Institut Jean Godinot, Reims), Y Otmezguine (Ho ˆpital
Henri Mondor, Cre ´teil), P Paycha (Clinique Escudie ´, Albi), M Petit
(Ho ˆpital Robert Debre ´, Paris), S Piperno-Neumann (Ho ˆpital
Avicenne, Bobigny), I Resche (Centre Rene ´ Gauducheau, Saint-
Herblain), JP Rieu (Centre hospitalier, Albi), F Rocher (Clinique
Sainte Marie, Chalon-sur-Sao ˆne), F Rousselot (Clinique Saint-
Germain, Brive), A Ruffion (rue Bataille, Lyon), H Sancho-Garnier
(Centre Val d’Aurelle, Montpellier), JB Sautron (Bagnols-en-Fore ˆt),
P Schaffer (Laboratoire d’e ´pide ´miologie et de sante ´ publique,
Strasbourg), JM Simon (Hopital Pitie ´-Salpe ´trie `re, Paris), JY Soret
(CHU Clinique Urologique, Angers), G Souweine (Conseil
scientifique de l’Andem, Venissieux), F Staerman (CHU de Reims,
Reims), M Steinling (CHRU Ho ˆpital Huriez, Lille), A Vieillefond
(Groupe hospitalier Cochin, Paris) and JJ Voigt (Institut Claudius
Re ´gaud, Toulouse).
This practice guideline has been developed with the collabora-
tion of the Association Franc ¸aise d’Urologie (AFU).
SORs for management of non-metastatic prostate cancer patients
A Villers et al
S58
British Journal of Cancer (2003) 89(Suppl 1), S50–S58 & 2003 FNCLCC